Mark D. Plinio - 29 Jul 2022 Form 4 Insider Report for Evelo Biosciences, Inc.

Role
Chief Commercial Officer
Signature
/s/ Daniel S. Char, Attorney-in-Fact for Mark Plinio
Issuer symbol
EVLO on OTC
Transactions as of
29 Jul 2022
Net transactions value
+$2,238
Form type
4
Filing time
14 Oct 2022, 16:24:59 UTC
Previous filing
01 Feb 2022
Next filing
02 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EVLO Common Stock Award $2,238 +1,250 +100% $1.79* 2,500 29 Jul 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Evelo Biosciences, Inc. 2018 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of February 1, 2022 through July 31, 2022. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.
F2 The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of July 29, 2022.
F3 In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of common stock on the Purchase Date of July 29, 2022.